These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 16915536

  • 1. Incremental prescription and drug costs during the years preceding diabetes diagnosis in primary care practices in Germany.
    Icks A, Haastert B, Giani G, Rathmann W.
    Exp Clin Endocrinol Diabetes; 2006 Jul; 114(7):348-55. PubMed ID: 16915536
    [Abstract] [Full Text] [Related]

  • 2. Trends in outpatient prescription drug costs in diabetic patients in Germany, 1994-2004.
    Rathmann W, Haastert B, Icks A, Giani G.
    Diabetes Care; 2007 Apr; 30(4):848-53. PubMed ID: 17392545
    [Abstract] [Full Text] [Related]

  • 3. [Costs of the treatment of hyperglycemia in patients with diabetes mellitus. The impact of age, type of therapy and complications: results of the German CoDiM study].
    von Ferber L, Köster I, Hauner H.
    Med Klin (Munich); 2006 May 15; 101(5):384-93. PubMed ID: 16685485
    [Abstract] [Full Text] [Related]

  • 4. [Prescribing behavior of primary care physicians in diabetes therapy: effect of drug budgeting].
    Jünger C, Rathmann W, Giani G.
    Dtsch Med Wochenschr; 2000 Feb 04; 125(5):103-9. PubMed ID: 10705882
    [Abstract] [Full Text] [Related]

  • 5. Sex differences in treatment patterns of six chronic diseases: an analysis from the German statutory health insurance.
    Stock SA, Stollenwerk B, Redaelli M, Civello D, Lauterbach KW.
    J Womens Health (Larchmt); 2008 Apr 04; 17(3):343-54. PubMed ID: 18338965
    [Abstract] [Full Text] [Related]

  • 6. Prescription of insulin glargine in primary care practices in Germany.
    Rathmann W, Haastert B, Riebel P, Schroeder-Bernhardi D, Kostev K, Huppertz E, Giani G.
    Exp Clin Endocrinol Diabetes; 2007 Apr 04; 115(4):252-6. PubMed ID: 17479442
    [Abstract] [Full Text] [Related]

  • 7. Epidemiology of complications and total treatment costs from diagnosis of Type 2 diabetes in Germany (ROSSO 4).
    Martin S, Schramm W, Schneider B, Neeser K, Weber C, Lodwig V, Heinemann L, Scherbaum WA, Kolb H.
    Exp Clin Endocrinol Diabetes; 2007 Sep 04; 115(8):495-501. PubMed ID: 17853332
    [Abstract] [Full Text] [Related]

  • 8. [Drug prescribing in primary health care for diabetic and non-diabetic patients: effect of therapeutic drug budgeting].
    Jünger C, Rathmann W, Giani G.
    Gesundheitswesen; 1999 Dec 04; 61(12):607-13. PubMed ID: 10666939
    [Abstract] [Full Text] [Related]

  • 9. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H, Kohlmann T, Landgraf W, Holle R, Pirk O, Scholten T.
    Dtsch Med Wochenschr; 2009 Jun 04; 134(23):1207-13. PubMed ID: 19472091
    [Abstract] [Full Text] [Related]

  • 10. Diabetes--prevalence and cost of illness in Germany: a study evaluating data from the statutory health insurance in Germany.
    Stock SA, Redaelli M, Wendland G, Civello D, Lauterbach KW.
    Diabet Med; 2006 Mar 04; 23(3):299-305. PubMed ID: 16492214
    [Abstract] [Full Text] [Related]

  • 11. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
    Pawaskar MD, Camacho FT, Anderson RT, Cobden D, Joshi AV, Balkrishnan R.
    Clin Ther; 2007 Jun 04; 29(6 Pt 1):1294-305. PubMed ID: 18036391
    [Abstract] [Full Text] [Related]

  • 12. Drug therapy of cardiovascular risk factors: guidelines versus reality in primary health care service.
    Marković BB, Kranjcević K, Reiner Z, Blazeković SM, Spehar SS.
    Croat Med J; 2005 Dec 04; 46(6):984-9. PubMed ID: 16342354
    [Abstract] [Full Text] [Related]

  • 13. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.
    Schöffski O, Breitscheidel L, Benter U, Dippel FW, Müller M, Volk M, Pfohl M.
    J Med Econ; 2008 Dec 04; 11(4):695-712. PubMed ID: 19450076
    [Abstract] [Full Text] [Related]

  • 14. Direct costs of diabetes mellitus in Germany - CoDiM 2000-2007.
    Köster I, Huppertz E, Hauner H, Schubert I.
    Exp Clin Endocrinol Diabetes; 2011 Jun 04; 119(6):377-85. PubMed ID: 21264804
    [Abstract] [Full Text] [Related]

  • 15. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
    Sun SX, Ye X, Lee KY, Dupclay L, Plauschinat C.
    Clin Ther; 2008 Jun 04; 30 Pt 2():2217-27. PubMed ID: 19281916
    [Abstract] [Full Text] [Related]

  • 16. Polypharmacy in primary care practices: an analysis using a large health insurance database.
    Grimmsmann T, Himmel W.
    Pharmacoepidemiol Drug Saf; 2009 Dec 04; 18(12):1206-13. PubMed ID: 19795368
    [Abstract] [Full Text] [Related]

  • 17. Diffusion into use of exenatide for glucose control in diabetes mellitus: a retrospective cohort study of a new therapy.
    Segal JB, Dy SM, Millman EA, Herbert R, Bass EB, Wu A.
    Clin Ther; 2007 Aug 04; 29(8):1784-94. PubMed ID: 17919559
    [Abstract] [Full Text] [Related]

  • 18. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.
    Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL.
    Clin Ther; 2006 Oct 04; 28(10):1712-25; discussion 1710-1. PubMed ID: 17157128
    [Abstract] [Full Text] [Related]

  • 19. [Drug prescriptions and costs in diabetic polyneuropathy].
    Rathmann W, Haastert B, Giani G.
    Dtsch Med Wochenschr; 1999 Jun 04; 124(22):681-6. PubMed ID: 10394347
    [Abstract] [Full Text] [Related]

  • 20. [Juvenile obesity and comorbidity type 2 diabetes mellitus (T2 DM) in Germany: development and cost-of-illness analysis].
    Wolfenstetter SB.
    Gesundheitswesen; 2006 Oct 04; 68(10):600-12. PubMed ID: 17099820
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.